MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich developing a cell therapy platform for the regeneration of skeletal muscle tissue, not only repairing damaged tissue but also increasing the regenerative potential of weakened muscles. Our initial area of focus is the treatment of stress urinary incontinence in women, supporting them respectfully throughout their journey to a healthy life.

Together, we aim to establish personalized, regenerative treatments as the primary standard of care. Our goal is to help the millions of patients suffering from seriously debilitating diseases to regain control over their life by offering them minimally invasive, low-risk treatments for the regeneration of skeletal muscle tissue.

MUVON Therapeutics is developing an autologous cell therapy platform for the treatment of diseases related to skeletal muscle damage or degradation. Our technology enables the targeted isolation of muscle precursor cells (MPCs) from muscle tissue, the controlled expansion of these cells and the regeneration of muscle tissue through injection of the expanded cells.

We are recruiting patients for our phase II clinical trial to treat stress urinary incontinence in women